Clinical

Dataset Information

0

Study of ESG401 in Adults With Solid Tumors


ABSTRACT: The primary objective in Phase I is to evaluate the safety and tolerability of ESG401 as a single agent administered in 21-day treatment cycles in previously treated participants with advanced epithelial cancer. In Phase II, the primary objective is to evaluate the safety and efficacy of ESG401 administered in 21-day treatment cycles at a dose selected in Phase I. Tumor types in the study will include: cervical, colorectal, endometrial, ovarian, esophageal, gastric adenocarcinoma, glioblastoma multiforme, head and neck cancers- squamous cell, hepatocellular, prostate, non-small-cell lung cancer, pancreatic, renal cell, small-cell lung cancer, non-triple negative breast cancer (non-TNBC), triple-negative breast cancer (TNBC) and metastatic urothelial cancer (mUC).

DISEASE(S): Neoplasms,ovarian,Neoplasms,colorectal,Neoplasms, Bladder,Urinary Bladder Neoplasms,Breast Neoplasms,Lung Neoplasms,Neoplasms, Breast,Neoplasm Of Stomach,Neoplasms,Colorectal Neoplasms,Neoplasms, Lung,Ovarian Neoplasms,Stomach Neoplasms

PROVIDER: 2377953 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2011-06-01 | E-GEOD-27447 | biostudies-arrayexpress
2014-06-11 | E-GEOD-58135 | biostudies-arrayexpress
2021-03-05 | PXD021201 | Pride
2015-09-24 | E-GEOD-69106 | biostudies-arrayexpress
2012-12-21 | E-GEOD-38959 | biostudies-arrayexpress
2011-06-01 | GSE27447 | GEO
2022-05-06 | GSE202316 | GEO
2025-01-04 | PXD048247 | JPOST Repository
2013-04-19 | GSE41970 | GEO
2021-02-01 | GSE45498 | GEO